Article

VEL products reinstated

Vision-Ease Lens (VEL) has reinstated the availability of nearly all of its product styles, 17 months after a fire at the company?s manufacturing facility in Jakarta, Indonesia, led to a temporary suspension of some styles. No employees were injured in the November, 2009 fire, but production was halted at the facility while it was rebuilt.

Ramsey, MN-Vision-Ease Lens (VEL) has reinstated the availability of nearly all of its product styles 17 months after a fire at the company’s manufacturing facility in Jakarta, Indonesia, led to a temporary suspension of some lens styles. No employees were injured in the November 2009 fire, but production was halted at the facility while it was rebuilt.

Earlier this year, VEL restarted production on the balance of its core polycarbonate lens line, and is now stocking and shipping Continua SFSV 71, 75, and 80 mm and Continua FSV 65, 75 mm lenses. Other previously reinstated products since the fire include: Continua Tintable FSV (Aspheric 65 mm, Spherical 75 mm), Tegra FSV (Aspheric 65 mm and 75 mm), Continua multifocals (D28, D35, 7x28, and 8x35), and all glass products.

VEL said its Continua FSVAR (Aspheric 65 mm, Spherical 75 mm) lenses have been discontinued and will be replaced with a new, upgraded version with Super-Hydro AR coating, set to launch in June 2011.

According to VEL, the rebuilt plant houses state-of-the-art manufacturing equipment, and meets international standards for natural disasters, including earthquakes and tsunamis, and houses the latest fire-suppressant technologies available.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.